ARS Pharmaceuticals, Inc. (SPRY) has reported solid financial results for the fourth quarter and full-year 2024, driven by the commercial launch of neffy, the first and only needle-free epinephrine treatment for severe allergic reactions.
neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30="" kilograms="" (33="" lbs.="" to="">< 66="" lbs.),="" expanding="" the="" reach="" of="" neffy="" to="" approximately="" 2="" million="" younger,="" school-aged="" children="" at="" risk="" of="" a="" severe="" allergic="">
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com